logo
Join/ Subscribe

Subscribe

We recognize the significance of content in the modern digital world. Sign up on our website to receive the most recent technology trends directly in your email inbox..


Safe and Secure

Free Articles

logo
Join/ Subscribe Us

Subscribe

We recognize the significance of content in the modern digital world. Sign up on our website to receive the most recent technology trends directly in your email inbox.





    We assure a spam-free experience. You can update your email preference or unsubscribe at any time and we'll never share your information without your consent. Click here for Privacy Policy.


    Safe and Secure

    Free Articles

    health

    KnowledgeNile is the one of the emerging technology content marketing organizations. 

    OneMedNet Announces Exciting New Collaboration with Bayer's AI Innovation Platform to Help Accelerate Healthcare AI Development
    OneMedNet Announces Exciting New Collaboration with Bayer’s AI Innovation Platform to Help Accelerate Healthcare AI Development
    MINNEAPOLIS, (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) ("OneMedNet" or the "Company"), a Real-World Data (RWD) platform — has announced its collaboration with Bayer's AI Innovation Platform (AIIP). By joining AIIP, the partnership aims to empower the developer teams of healthcare organizations and startups in building scalable and compliant AI-powered medical imaging software products. "We […]
    ADMA Biologics Announces Partial Paydown of Revolving Credit Facility
    ADMA Biologics Announces Partial Paydown of Revolving Credit Facility
    Cash on Hand Utilized to Repay $30 Million of Revolving Credit Facility to Ares Capital with No Prepayment Penalties Lowers ADMA’s Total Debt to $105 Million, a 22% Reduction Further Supports Earnings Growth Outlook RAMSEY, N.J. and BOCA RATON, Fla., Aug. 14, 2024 -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end […]
    Greenwich LifeSciences Set to Join Russell 2000 Index Again
    Greenwich LifeSciences Set to Join Russell 2000 Index Again
    STAFFORD, Texas, June 26, 2024 -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of […]
    Scroll to Top